Resistant Hypertension Optimal Treatment

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.

Also called NCT01643434

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01643434
Other papers using this trial's data
  • Resistant hypertension optimal treatment trial: a randomized controlled trial Clinical cardiology, 2014-01 DOI, PubMed 24338935, PMC6649632 Not in the PMC Open Access subset.
  • Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment) Hypertension (Dallas, Tex. : 1979), 2018-04 DOI, PubMed 29463627

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01643434. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Resistant Hypertension Optimal Treatment
Acronym
ReHOT
Condition
Hypertension
Intervention (Drug)
Spironolactone
Intervention (Drug)
Clonidine
Lead sponsor
Instituto do Coracao (class: other government)
Collaborator
Conselho Nacional de Desenvolvimento Científico e Tecnológico (class: other government)

Record details

Record id
cardio:ct-nct01643434
Content hash
3e1df73ae450bcc7645df6acf165c4aa621773cd25cf6d909ca897811b6b2eb0